Efficacy of intravenous aspirin use in patients with acute coronary syndrome / 中华心血管病杂志

ABSTRACT

<p><b>OBJECTIVE</b>To compare the efficacy of intravenous versus oral aspirin use in patients with acute coronary syndrome (ACS).</p><p><b>METHODS</b>ACS patients were randomly treated with intravenous aspirin (300 mg/d, IA, n = 30), low oral aspirin (100 mg/d, OA1, n = 32) or high oral aspirin (300 mg/d, OA2, n = 33). Aspirin sensitivity was tested by optical platelet aggregation using adenosine diphosphate (ADP) and arachidonic acid (AA). The serum CD62p contents were examined by Flow cytometry.</p><p><b>RESULTS</b>Platelet aggregation expressed as ratio of reduction of ADP and AA post various aspirin were similar among 3 groups [IA ADP (12.0 +/- 10.4)%, AA (6.7 +/- 11.2)%; OA1 ADP (6.0 +/- 14.6)%, AA (6.9 +/- 12.3)%; OA2 ADP (9.4 +/- 16.6)%, AA (7.3 +/- 13.0)%, all P > 0.05]. CD62p decreasing level post various aspirin were also similar among groups [IA (10.9 +/- 18.6)%, OA1 (9.0 +/- 11.8)%, OA2 (7.1 +/- 15.7)%, all P > 0.05]. Side-effects and MACE post various aspirin use were comparable among groups.</p><p><b>CONCLUSION</b>Inhibiting efficacy on platelets function by intravenous aspirin (300 mg/d) was comparable to that of by oral aspirin (100 mg/d, 300 mg/d) in patients with acute coronary syndrome and could be used as an alternative route for patients who can't take oral aspirin.</p>